Please login to the form below
Galafold
This page shows the latest Galafold news and features for those working in and with pharma, biotech and healthcare.
Amicus forms gene therapy manufacturing partnership with Catalent
Amicus has one rare disease medicine already on the market, Galafold for Fabry disease, with an enzyme replacement therapy (AT-GAA) for Pompe disease in its late stage pipeline, to which
Latest news
-
Orphan drugs from Biogen and Amicus win UK Prix Galien
Galafold (migalastat) is an oral medication for the treatment of Fabry disease, a rare lysosomal metabolic storage condition. ... He commented on Galafold: “For the 855 patients in the UK, Fabry disease will cut their life expectancy by 15-20 years.
-
Daily Brief: Orchard raises $150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval
Amicus’s Galafold gains FDA approval, set to rival Fabrayzme. Amicus Therapeutics has received FDA approval for Galafold, the first oral therapy for the rare Fabry disease. ... Galafold is a long-term treatment for adult patients with specific genetic
-
Orphan drugs dominate UK Prix Galien shortlist, medtech debuts
This year, the judges concluded that just two entrants were worthy of being shortlisted for the Innovative Product Award; Sanofi (Dupixent) and Amicus (Galafold). ... Seven companies have been shortlisted for the Orphan Product Award; Amicus (Galafold),
-
Amicus Therapeutics launches Fabry treatment Galafold in Italy
John Crowley, Amicus chairman and CEO, said: "The commercial launch of Galafold in Italy is a significant milestone for the Fabry community. ... Galafold is the first orally administered alternative to the current crop of injectable enzyme replacement
-
Amicus gets NICE green light for Fabry drug
Galafold is scheduled for its next review in 2020, but NICE said that could come sooner if the prices of ERTs change in the interim. ... Fabry disease affects an estimated 855 people in England, of whom around 140 would be eligible for treatment with
More from news
Approximately 6 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Pharma deals in August 2015
Acquisition of remaining rights. 1034. Scioderm. Amicus. Galafold [migalastat] for Fabry's disease.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- A new era for UK-Japanese scientific research relations
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- FDA issues innovative proposal to increase nonprescription drug access
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- My journey advancing the science in pulmonary hypertension
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
PMHub
Empowering Strategic Performance Ltd
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
